Therapeutics News and Research

RSS

Non-invasive ultrasound technology can treat Alzheimer's disease, restore memory

Queensland scientists have found that non-invasive ultrasound technology can be used to treat Alzheimer's disease and restore memory.

13 Mar 2015

McGill researchers identify key mechanism by which environmental factors influence traits

Until now scientists have believed that the variations in traits such as our height, skin colour, tendency to gain weight or not, intelligence, tendency to develop certain diseases, etc., all of them traits that exist along a continuum, were a result of both genetic and environmental factors. But they didn't know how exactly these things worked together.

12 Mar 2015

Ember Therapeutics, Mariel Therapeutics sign definitive merger agreement

Ember Therapeutics, Inc., a Boston-based biotechnology company dedicated to the discovery and development of novel obesity and diabetic related therapies, and Mariel Therapeutics, a privately held, New York-based biotechnology company developing targeted therapies for osteoarthritis and kidney fibrosis using Bone Morphogenetic Protein (BMP)-7, jointly announce today that they have entered into a definitive agreement to merge the two companies.

12 Mar 2015

Promising new natural treatment for Alzheimer's disease nears clinical trial

A promising new natural treatment for Alzheimer's disease is moving toward clinical trials. This will be a major step forward as there is nothing on the market that slows the progression of Alzheimer's.

12 Mar 2015

Wistar awarded grant to create Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium

The Jayne Koskinas Ted Giovanis Foundation awarded The Wistar Institute a $1.1 million grant to create The Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium at The Wistar Institute. The Consortium will support the highly synergistic, multidisciplinary research projects of three Wistar scientists dedicated to advancing breast cancer research.

12 Mar 2015

BeiGene chooses SAFC's CHOZN Platform to support oncology drug development

Sigma-Aldrich Corporation today announced that SAFC Commercial, its custom manufacturing services business unit, has entered a commercial sales and service contract with leading biopharmaceutical company, BeiGene.

11 Mar 2015

Somna Therapeutics receives FDA clearance to market REZA BAND UES Assist Device in U.S.

Somna Therapeutics today announced that the U.S. Food and Drug Administration cleared the REZA BAND UES Assist Device for marketing in the U.S. The REZA BAND is a ground-breaking, new, externally-worn, non-medication, non-surgical medical device designed to reduce symptoms of laryngopharyngeal reflux (LPR) by stopping regurgitation of stomach contents through the upper esophageal sphincter (UES).

10 Mar 2015

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

10 Mar 2015

Impax Laboratories acquires Tower Holdings and Lineage Therapeutics

Impax Laboratories, Inc. today announced that it has completed its acquisition of Tower Holdings, Inc. (including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC), and Lineage Therapeutics Inc. (together, the "Companies").

10 Mar 2015

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121.

From Advanced Cell Diagnostics 9 Mar 2015

EMD Serono executes amendment agreement with Opexa for development of Tcelna (imilecleucel-T)

EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).

9 Mar 2015

Phico Therapeutics gets £2.25M Translation Award to develop SASPject PT4 antibiotic for E. coli, K. pneumoniae

Phico Therapeutics, a biotechnology company developing a novel platform technology for a new generation of antibiotics aimed at overcoming antibacterial resistance, has been awarded a £2.25M Translation Award by the Wellcome Trust to develop its SASPject PT4 antibiotic, aimed at Escherichia coli and Klebsiella pneumoniae.

9 Mar 2015

Oraya's IRay Radiotherapy system gets CE Mark to treat choroidal metastases

Oraya Therapeutics announced today that the Oraya IRay® Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from primary sites in the breast or lung.

6 Mar 2015

Mallinckrodt enters into definitive agreement to acquire Ikaria

Mallinckrodt plc, a leading global specialty biopharmaceutical company, and Ikaria, Inc. a privately-held critical care company, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria, Inc. from a Madison Dearborn-led investor group in a transaction valued at approximately $2.3 billion.

5 Mar 2015

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

Asterias Biotherapeutics, Inc., a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation's top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).

5 Mar 2015

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.

4 Mar 2015

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

Prime Therapeutics LLC received the Pharmacy Benefit Management Institute's 2015 Rx Innovation Award today in recognition of its innovative "Specialty Drug Watch List."

3 Mar 2015

NeuroPerspective features comprehensive reviews of schizophrenia, spinal cord injury

NI Research has released the March/April issue of NeuroPerspective, which features comprehensive reviews of two major areas: Schizophrenia and Spinal cord injury.

3 Mar 2015

Damon Runyon holds fourth annual Accelerating Cancer Cures Research Symposium

Today, the Damon Runyon Cancer Research Foundation held the fourth annual Accelerating Cancer Cures Research Symposium. The yearly meeting is designed to encourage collaboration between cancer researchers in industry and their counterparts in academia in order to overcome many of the issues that currently impede progress against cancer.

3 Mar 2015

Chrono Therapeutics gets support to develop SmartStop device for smoking cessation

Chrono Therapeutics, a pioneer in digital drug products, today announced an investment by Rock Health, the leading seed fund in digital health, to support the advancement of Chrono's SmartStop programmable transdermal drug delivery system and real-time behavioral support program for smoking cessation.

3 Mar 2015

Therapeutics News and Research

Non-invasive ultrasound technology can treat Alzheimer's disease, restore memory

McGill researchers identify key mechanism by which environmental factors influence traits

Ember Therapeutics, Mariel Therapeutics sign definitive merger agreement

Promising new natural treatment for Alzheimer's disease nears clinical trial

Wistar awarded grant to create Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium

BeiGene chooses SAFC's CHOZN Platform to support oncology drug development

Somna Therapeutics receives FDA clearance to market REZA BAND UES Assist Device in U.S.

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

Impax Laboratories acquires Tower Holdings and Lineage Therapeutics

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

EMD Serono executes amendment agreement with Opexa for development of Tcelna (imilecleucel-T)

Phico Therapeutics gets £2.25M Translation Award to develop SASPject PT4 antibiotic for E. coli, K. pneumoniae

Oraya's IRay Radiotherapy system gets CE Mark to treat choroidal metastases

Mallinckrodt enters into definitive agreement to acquire Ikaria

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

NeuroPerspective features comprehensive reviews of schizophrenia, spinal cord injury

Damon Runyon holds fourth annual Accelerating Cancer Cures Research Symposium

Chrono Therapeutics gets support to develop SmartStop device for smoking cessation

Industry Focus eBook - Biotechnology (4th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News